Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
72
XPH Quote, Financials, Valuation and Earnings
Last price:
$54.23
Seasonality move
:
3.83%
Day range:
$53.81 - $54.42
52-week range:
$35.22 - $54.90
Dividend yield:
0.93%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
21.2K
Avg. volume:
46.4K
1-year change:
17.97%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
$54.29 | -- | -- | -- | $0.10 | 0.93% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$212.83 | -- | -- | -- | $1.17 | 0.55% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$82.06 | -- | -- | -- | $0.23 | 0.49% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$105.25 | -- | -- | -- | $0.24 | 0.95% | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
$31.80 | -- | -- | -- | $0.06 | 0.72% | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
$89.39 | -- | -- | -- | $0.03 | 0.08% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | 0.588 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 0.657 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.859 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.316 | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | 0.671 | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | 1.031 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
State Street SPDR S&P Pharmaceuticals ETF vs. Competitors
-
Which has Higher Returns XPH or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to State Street SPDR S&P Pharmaceuticals ETF's net margin of --. State Street SPDR S&P Pharmaceuticals ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About XPH or FBT?
State Street SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Pharmaceuticals ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe State Street SPDR S&P Pharmaceuticals ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings XPHState Street SPDR S&P Pharmaceuticals ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is XPH or FBT More Risky?
State Street SPDR S&P Pharmaceuticals ETF has a beta of 0.657, which suggesting that the stock is 34.268% less volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.562%.
-
Which is a Better Dividend Stock XPH or FBT?
State Street SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 0.93%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0.55% to investors and pays a quarterly dividend of $1.17 per share. State Street SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or FBT?
State Street SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. State Street SPDR S&P Pharmaceuticals ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, State Street SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Pharmaceuticals ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns XPH or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to State Street SPDR S&P Pharmaceuticals ETF's net margin of --. State Street SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About XPH or PBE?
State Street SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe State Street SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHState Street SPDR S&P Pharmaceuticals ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is XPH or PBE More Risky?
State Street SPDR S&P Pharmaceuticals ETF has a beta of 0.657, which suggesting that the stock is 34.268% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.822, suggesting its less volatile than the S&P 500 by 17.787%.
-
Which is a Better Dividend Stock XPH or PBE?
State Street SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 0.93%. Invesco Biotechnology & Genome ETF offers a yield of 0.49% to investors and pays a quarterly dividend of $0.23 per share. State Street SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or PBE?
State Street SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. State Street SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, State Street SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns XPH or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to State Street SPDR S&P Pharmaceuticals ETF's net margin of --. State Street SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About XPH or PJP?
State Street SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe State Street SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHState Street SPDR S&P Pharmaceuticals ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is XPH or PJP More Risky?
State Street SPDR S&P Pharmaceuticals ETF has a beta of 0.657, which suggesting that the stock is 34.268% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.387%.
-
Which is a Better Dividend Stock XPH or PJP?
State Street SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 0.93%. Invesco Pharmaceuticals ETF offers a yield of 0.95% to investors and pays a quarterly dividend of $0.24 per share. State Street SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or PJP?
State Street SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. State Street SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, State Street SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns XPH or RSPH?
Invesco S&P 500 Eql Wght Health Care ETF has a net margin of -- compared to State Street SPDR S&P Pharmaceuticals ETF's net margin of --. State Street SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco S&P 500 Eql Wght Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- -
What do Analysts Say About XPH or RSPH?
State Street SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P 500 Eql Wght Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco S&P 500 Eql Wght Health Care ETF, analysts believe State Street SPDR S&P Pharmaceuticals ETF is more attractive than Invesco S&P 500 Eql Wght Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHState Street SPDR S&P Pharmaceuticals ETF0 0 0 RSPHInvesco S&P 500 Eql Wght Health Care ETF0 0 0 -
Is XPH or RSPH More Risky?
State Street SPDR S&P Pharmaceuticals ETF has a beta of 0.657, which suggesting that the stock is 34.268% less volatile than S&P 500. In comparison Invesco S&P 500 Eql Wght Health Care ETF has a beta of 0.923, suggesting its less volatile than the S&P 500 by 7.663%.
-
Which is a Better Dividend Stock XPH or RSPH?
State Street SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 0.93%. Invesco S&P 500 Eql Wght Health Care ETF offers a yield of 0.72% to investors and pays a quarterly dividend of $0.06 per share. State Street SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco S&P 500 Eql Wght Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or RSPH?
State Street SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco S&P 500 Eql Wght Health Care ETF quarterly revenues of --. State Street SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco S&P 500 Eql Wght Health Care ETF's net income of --. Notably, State Street SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco S&P 500 Eql Wght Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco S&P 500 Eql Wght Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- --
-
Which has Higher Returns XPH or XHE?
State Street SPDR S&P Health Care Equipment ETF has a net margin of -- compared to State Street SPDR S&P Pharmaceuticals ETF's net margin of --. State Street SPDR S&P Pharmaceuticals ETF's return on equity of -- beat State Street SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About XPH or XHE?
State Street SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Pharmaceuticals ETF has higher upside potential than State Street SPDR S&P Health Care Equipment ETF, analysts believe State Street SPDR S&P Pharmaceuticals ETF is more attractive than State Street SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHState Street SPDR S&P Pharmaceuticals ETF0 0 0 XHEState Street SPDR S&P Health Care Equipment ETF0 0 0 -
Is XPH or XHE More Risky?
State Street SPDR S&P Pharmaceuticals ETF has a beta of 0.657, which suggesting that the stock is 34.268% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Equipment ETF has a beta of 1.125, suggesting its more volatile than the S&P 500 by 12.522%.
-
Which is a Better Dividend Stock XPH or XHE?
State Street SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 0.93%. State Street SPDR S&P Health Care Equipment ETF offers a yield of 0.08% to investors and pays a quarterly dividend of $0.03 per share. State Street SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or XHE?
State Street SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Equipment ETF quarterly revenues of --. State Street SPDR S&P Pharmaceuticals ETF's net income of -- is lower than State Street SPDR S&P Health Care Equipment ETF's net income of --. Notably, State Street SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Pharmaceuticals ETF is -- versus -- for State Street SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
